David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)
May 25, 2023 11:12 AM EDT
R&D
Pharma

Lil­ly gears up trio of PhI­II tri­als for its oral GLP-1 amid No­vo Nordisk, Pfiz­er com­pe­ti­tion

Kyle LaHucik

Senior Reporter

As No­vo Nordisk and Pfiz­er dis­close some da­ta on their oral weight loss drugs in Phase III and II, re­spec­tive­ly, Eli Lil­ly is beef­ing up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

Eli Lil­ly turns to South Ko­re­an RNA edit­ing biotech for hear­ing loss in deal worth $1.3B

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

A service from the Financial Times